Bristol-Myers Squibb's innovative melanoma treatment Yervoy receives
industry's highest honour
Prix Galien Canada for innovation awarded to first treatment to show survival
benefit for patients with the most deadly form of skin cancer
MONTREAL, Nov. 21, 2013 /CNW/ - Bristol-Myers Squibb Canada is pleased to
announce that YERVOY(®) (ipilimumab) a novel immuno-oncology therapy for
metastatic melanoma has been awarded the Prix Galien Canada 2013 Innovative
Product Award. This award, presented at a ceremony last night in Montreal,
recognizes the significant impact Yervoy has had in treating this most
aggressive and deadly form of skin cancer.
Yervoy, which has now been approved in more than 40 countries around the
world, was approved by Health Canada in February 2012 as the first and only
treatment for advanced melanoma proven to extend survival in a phase three
trial. Yervoy is indicated for the treatment of unresectable or metastatic
melanoma in patients who have failed or do not tolerate other systemic therapy
for advanced disease.
"We are very proud of the difference Yervoy has made, and will continue to
make, in the lives of Canadians with metastatic melanoma and their families,"
said Awny Farajallah, Vice-President, Medical, Bristol-Myers Squibb Canada.
"Yervoy represents the important progress we have made in immuno-oncology, a
rapidly-evolving field of cancer research and treatment focused on harnessing
the power of the body's immune system to fight cancer."
Unlike traditional therapies that target the tumour, immuno-oncology agents
are designed to harness the natural capabilities of the patient's immune
system to fight cancer by targeting the very same pathways tumor cells use to
evade recognition and destruction. Yervoy specifically blocks cytotoxic T
lymphocyte-associated antigen-4 (CTLA-4), which plays a role in suppressing
the normal immune response. Yervoy blocks that suppression to allow the immune
system to respond to melanoma cancer cells.
Yervoy clinical evidence
In a pivotal randomized phase three clinical study, the median overall
survival was 10 months for Yervoy and six months for the comparator treatment,
a peptide vaccine (gp100). Yervoy has also demonstrated durable long-term
survival in some patients. The Kaplan-Meier estimated survival rate with
Yervoy at both one and two years was almost doubled when measured against
patients treated with gp100, 46 per cent versus 25 per cent at one year and 24
per cent versus 14 per cent at two years. Data were recently presented at the
European Cancer Congress in Amsterdam in September on long-term survival
results from a pooled analysis of 12 studies of Yervoy at different doses and
regimens in more than 1,800 patients with metastatic or locally advanced or
unresectable melanoma, which showed that approximately 22% of patients were
alive at three years with some followed for up to 10 years.
The types of adverse events (AEs) attributed to Yervoy are generally related
to its mechanism of action, that is, immune-based. Immune-mediated adverse
reactions, sometimes fatal, include enterocolitis, intestinal perforation,
hepatitis, dermatitis, neuropathy, endocrinopathy as well as toxicity in other
organ systems. Adverse events associated with Yervoy are managed by the
administration of systemic corticosteroids, dose discontinuation and/or the
use of other immuno-suppressants.
About the Prix Galien Canada
The Prix Galien is the most prestigious award in the field of Canadian
pharmaceutical research and innovation. Referred to as the Nobel Prize of
pharmaceutical research, it recognizes the efforts and achievements of
pharmaceutical research and development. The Prix Galien Canada is a branch of
Innovation Life Canada. www.prix-galien-canada.com.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of
Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help patients
prevail over serious diseases. For more information, please visit
YERVOY(® )is a registered trademark of Bristol-Myers Squibb Company.
SOURCE Bristol-Myers Squibb Canada
Monica Flores Senior Manager, Corporate and Business Communications
Bristol-Myers Squibb Canada 514-333-3845 email@example.com
To view this news release in HTML formatting, please use the following URL:
CO: Bristol-Myers Squibb Canada
NI: MTC ENT HEA
-0- Nov/21/2013 10:59 GMT
Press spacebar to pause and continue. Press esc to stop.